natgillin/translations-raw huggingface dataset:
A therapeutic antibody or antigen binding fragment thereof according to any one of claims 1 to 7 for use in the treatment of a disease or disorder selected from the group consisting of; Allergic asthma, severe asthma, difficult asthma, brittle asthma, nocturnal asthma, premenstrual asthma, steroid resistant asthma, steroid dependent asthma, aspirin induced asthma, adult-onset asthma, paediatric asthma, atopic dermatitis, allergic rhinitis, Crohn's disease, COPD, fibrotic diseases or disorders such as idiopathic pulmonary fibrosis, progressive systemic sclerosis, hepatic fibrosis, hepatic granulomas, schistosomiasis, leishmaniasis, diseases of cell cycle regulation such as Hodgkins disease, B cell chronic lymphocytic leukaemia. 
Terapijsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 27, naznačeno time što je namijenjeno liječenju bolesti ili poremećaja koje se bira iz skupine koju čine: alergijska astma, teška astma, teško izlječiva astma, krhka astma, noćna astma, premenstrualna astma, astma otporna na steroide, astma ovisna o steroidima, astma uzrokovana aspirinom, astma s početkom u odrasloj dobi, astma s početkom u dječjoj dobi, atopični dermatitis, alergijski rinitis, Crohnova bolest, COPD, fibrotične bolesti ili poremećaji, poput idiopatske plućne fibroze, progresivne sistemne skleroze, jetrene fibroze, jetrenih granuloma, shistosomijaza, lišmanijaza, bolesti regulacije staničnog ciklusa, poput Hodgkinove bolesti, B-stanica kronična limfocitni leukemia.
An antibody of any one of claims 1 to 10 and an anti-IL-4 monoclonal antibody such as pascolizumab for use in the treatment of a disease or disorder selected from the group consisting of; Allergic asthma, severe asthma, difficult asthma, brittle asthma, nocturnal asthma, premenstrual asthma, steroid resistant asthma, steroid dependent asthma, aspirin induced asthma, adult-onset asthma, paediatric asthma, atopic dermatitis, allergic rhinitis, Crohn's disease, COPD, fibrotic diseases or disorders such as idiopathic pulmonary fibrosis, progressive systemic sclerosis, hepatic fibrosis, hepatic granulomas, schistosomiasis, leishmaniasis, diseases of cell cycle regulation such as Hodgkins disease, B cell chronic lymphocytic leukaemia. 
Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 27 i monoklonsko protutijelo protiv IL-4, poput paskolizumaba, naznačena time što su namijenjena liječenju bolesti ili poremećaja koje se bira iz skupine koju čine: alergijska astma, teška astma, teško izlječiva astma, krhka astma, noćna astma, premenstrualna astma, astma otporna na steroide, astma ovisna o steroidima, astma uzrokovana aspirinom, astma s početkom u odrasloj dobi, astma s početkom u dječjoj dobi, atopični dermatitis, alergijski rinitis, Crohnova bolest, COPD, fibrotične bolesti ili poremećaji, poput idiopatske plućne fibroze, progresivne sistemne skleroze, jetrene fibroze, jetrenih granuloma, shistosomijaza, lišmanijaza, bolesti regulacije staničnog ciklusa, poput Hodgkinove bolesti, kronične limfocitne leukemije B-stanica.
Process of activation of a landfill of municipal solid waste (MSW) dried to a humidity content lower than 20%, characterised in that it provides for the feeding of water into the landfill until humidity contents of around 30-60% are reached and triggering of a process of anaerobic digestion with production of biogas (40-50% methane). 
Postupak aktivacije odlagališta komunalnog krutog otpada (MSW), čiji je sadržaj vlage pomoću aerobne obrade spušten ispod 20% težinski, koji je položen na vodo-nepropusnu podlogu (T) i prekriven po vrhu slojem gline niske propusnosti na plinove i tekućine, naznačen time da se dovođenjem vode u odlagalište podigne sadržaj vlage na 30-60% težinski, i time izazove anaerobno razlaganje i razvijanje bioplina koji sadrži 40-50%metana.
Process according to claim 1 or 2, characterised in that it provides for recycling of the percolate, after possible treatment of the same, for use in addition to or in place of the water for activation of the MSW or BIOCUBES. 
Postupak prema 1. ili 2. zahtjevu, naznačen time da se procjedne vode odlagališta, nakon eventualne obrade, recikliraju i koriste kao dodatak ili umjesto vode za aktivaciju MSW-a ili komprimiranih bala.
Use of a compound as claimed in any of claims 1-6 in the manufacture of a medicament for the treatment of a condition in a mammal for which the modulation of dopamine D3 receptors is beneficial, wherein the condition is psychosis or a psychotic condition, or is substance abuse. 
[image] gdje su R3 i R4 definirani kao u patentnom zahtjevu 1. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1-20, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje psihoze ili psihotičnog stanja, ili zloupotrebe tvari.
A compound as claimed in any of claims 1-6 for use in the treatment of psychosis or a psychotic condition. A compound as claimed in any of claims 1-6 for use in the treatment of substance abuse. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1-20, naznačen time što je namijenjen upotrebi liječenju psihoze ili psihotičnog stanja, ili liječenju zloupotrebe tvari.
The vaccine composition according Claim 1, wherein the conjugation ratio between rP64K carrier protein and the hrEGF is 12.04:24.05 nmolar. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da konjugacijski omjer između rP64K nosača proteina i hrEGF je 12,04:24,05 nmola.
The vaccine composition according Claim 1 wherein said composition is an homogenous mix of the conjugated hrEGF-rP64K being free of others molecular species like hrEGF polymers or free hrEGF. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je spomenuti sastav homogena mješavina konjugirane hrEGF-rP64K, koja je oslobođena od ostalih vrsta molekula kao što su hrEGF polimeri ili slobodna hrEGF.
The vaccine composition according Claim 1 wherein the homogenous mix of the conjugated hrEGF-rP64K is free of glutaraldehyde. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je homogena mješavina konjugirane hrEGF-rP64K oslobođena od glutaraldehida.
The vaccine composition according Claim 1 wherein the homogenous mix of the conjugated hrEGF-rP64K is able to induce an increase of at least 10 times the anti-EGF antibodies titters in the serum of immunized mammals. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je homogena mješavina konjugirane hrEGF-rP64K sposobna inducirati najmanje deseterostruko povećanje titera anti-EGF protutijela u serumu od imuniziranih sisavaca.
The vaccine composition according Claim 1 wherein the homogenous mix of the conjugated hrEGF-rP64K is able to induce an increase of at least 10 times the anti-EGF antibodies titters in the serum of humans. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je homogena mješavina konjugirane hrEGF-rP64K sposobna inducirati najmanje deseterostruko povećanje titera anti-EGF protutijela u serumu od ljudi.
The vaccine composition according Claim 1 wherein the homogenous mix of the conjugated hrEGF-rP64K is able to induce an increase of at least 100 times the anti-EGF antibodies titters in the serum of humans. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je homogena mješavina konjugirane hrEGF-rP64K sposobna inducirati najmanje stostruko povećanje titera anti-EGF protutijela u serumu od ljudi.
A procedure for obtaining the vaccine composition of claim 1 under sanitary standard wherein said procedure comprises appropriate conditions for the covalent conjugation of the EGF to the rP64K carrier protein and purification of the molecular complex, by using an ultrafiltration membrane, to remove the biologically inactive conjugated species and other chemical impurities. 
Postupak dobivanja sastava cjepiva prema zahtjevu 1, po zdravstvenim standardima, naznačen time, da spomenuti postupak obuhvaća prikladne uvjete za kovalentnu konjugaciju EGF-a na nosač proteina rP64K i purifikaciju molekularnog kompleksa, uporabom ultrafiltracijske membrane, za odstranjivanje biološki neaktivnih konjugiranih vrsta i ostalih kemijskih nečistoća.
The procedure of Claim11, wherein the conjugation reaction consists of a single step that begins mixing the hrEGF protein previously concentratiod (>6 mg/mL) and the P64K protein (≥1 mg/mL) in the conjugation reactor, and then adding to the mixture solution PBS/MgCl2 (pH 6.8-7.2) and the conjugation solution of glutaraldehyde 0.5%, and said mixture is incubated at 22°C± 2°C with continuous stirring for two hours. 
Postupak prema zahtjevu 9, naznačen time, da se konjugacijska reakcija sastoji od jednog koraka koji počinje miješanjem prethodno koncentriranih (>6 mg/mL) proteina hrEGF i (≥1 mg/mL) proteina P64K u konjugacijskom reaktoru, onda nastavlja dodavanjem PBS/MgCl2 (pH 6,8-7,2) i konjugacijske otopine od 0,5% glutaraldehida u mješavinu, te se tada spomenuta mješavina inkubira na 22°C ± 2°C s neprekidnim miješanjem u vremenu od dva sata.
The procedure for obtaining the vaccine composition according to Claim 14, wherein the conjugated protein is purified by a ultrafiltration/diafiltration method using a membrane having a pore size of 50 kDa. 
Postupak za dobivanje sastava cjepiva prema zahtjevu 12, naznačen time, da se konjugirani protein purificira metodom ultrafiltracije/dijafiltracije uporabom membrane koja ima veličinu pora od 50 kDa ili 100 kDa.
The vaccine composition comprising as active principle the conjugated protein hrEGFrP64K, wherein the final concentration of the total protein is in the range 1 - 12 mg/mL. 
Sastav cjepiva prema zahtjevu 1, koji kao aktivni sastavni element sadrži konjugirani protein hrEGF-rP64K, naznačen time, da je konačna koncentracija ukupnog proteina u rasponu od 1 do 12 mg/mL.
A vaccine composition comprising as active principle the protein conjugated hrEGF-rP64K, wherein each P64K protein molecule is bound to two hrEGF molecules and wherein the vaccine composition comprises at least 90% of the active principle . 
Sastav cjepiva, naznačen time, da kao aktivni sastavni element sadrži konjugirani protein hrEGF-rP64K, pri čemu je svaka molekula proteina P64K vezana za dvije hrEGF molekule, pri čemu sastav cjepiva sadrži najmanje 90% aktivnog sastavnog elementa.
The vaccine composition according Claim 1, wherein said composition is a homogenous mixture of the conjugated hrEGF-rP64K being free of other molecular species like hrEGF polymers or free hrEGF. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je spomenuti sastav homogena mješavina konjugirane hrEGF-rP64K, koja je oslobođena od ostalih vrsta molekula kao što su hrEGF polimeri ili slobodna hrEGF.
The vaccine composition according Claim 1, wherein the homogenous mixture of the conjugated hrEGF-rP64K is free of glutaraldehyde. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je homogena mješavina konjugirane hrEGF-rP64K oslobođena od glutaraldehida.
The vaccine composition according Claim 2, wherein the homogenous mixture of the conjugated hrEGF-rP64K additionally contains an appropriate adjuvant, selected from the group comprising aluminium hydroxide or Montanide. 
Sastav cjepiva prema zahtjevu 2, naznačen time, da homogena mješavina konjugirane hrEGF-rP64K dodatno sadrži prikladan adjuvans, odabran iz skupine koja sadrži aluminijev hidroksid ili Montanid.
The vaccine composition according Claim 1, wherein the homogenous mixture of the conjugated hrEGF-rP64K is able to induce an increase of at least 10 times the anti-EGF antibodies titers in the serum of immunized mammals. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je homogena mješavina konjugirane hrEGF-rP64K sposobna inducirati najmanje deseterostruko povećanje titera anti-EGF protutijela u serumu od imuniziranih sisavaca.
The vaccine composition according Claim 1, wherein the homogenous mixture of the conjugated hrEGF-rP64K is able to induce an increase of at least 10 times the anti-EGF antibodies titers in the serum of humans. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je homogena mješavina konjugirane hrEGF-rP64K sposobna inducirati najmanje deseterostruko povećanje titera anti-EGF protutijela u serumu od ljudi.
The vaccine composition according Claim 1, wherein the homogenous mixture of the conjugated hrEGF-rP64K is able to induce an increase of at least 100 times the anti-EGF antibodies titers in the serum of humans. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je homogena mješavina konjugirane hrEGF-rP64K sposobna inducirati najmanje stostruko povećanje titera anti-EGF protutijela u serumu od ljudi.
The procedure of Claim 9, wherein the conjugation reaction consists of a single step that begins mixing the hrEGF protein previously concentrated (>6 mg/mL) and the P64K protein (≥1 mg/mL) in the conjugation reactor, and then adding to the mixture solution PBS/MgCl2 (pH 6:8-7.2) and the conjugation solution of glutaraldehyde 0.5%, and said mixture is incubated at 22°C± 2°C with continuous stirring for two hours. 
Postupak prema zahtjevu 9, naznačen time, da se konjugacijska reakcija sastoji od jednog koraka koji počinje miješanjem prethodno koncentriranih (>6 mg/mL) proteina hrEGF i (≥1 mg/mL) proteina P64K u konjugacijskom reaktoru, onda nastavlja dodavanjem PBS/MgCl2 (pH 6,8-7,2) i konjugacijske otopine od 0,5% glutaraldehida u mješavinu, te se tada spomenuta mješavina inkubira na 22°C ± 2°C s neprekidnim miješanjem u vremenu od dva sata.
The procedure for obtaining the vaccine composition according to Claim 12, wherein the conjugated protein is purified by a ultrafiltration/diafiltration method using a membrane having a pore size of 50 kDa or 100 kDa. 
Postupak za dobivanje sastava cjepiva prema zahtjevu 12, naznačen time, da se konjugirani protein purificira metodom ultrafiltracije/dijafiltracije uporabom membrane koja ima veličinu pora od 50 kDa ili 100 kDa.
The vaccine composition according to claim 1 comprising as active principle the conjugated protein hrEGFrP64K, wherein said vaccine composition is purified by the procedure according to any of claims 9-13 
Sastav cjepiva prema zahtjevu 1, koji kao aktivni sastavni element sadrži konjugirani protein hrEGF-rP64K, naznačen time, da se spomenuti sastav cjepiva purificira postupkom prema bilo kojem zahtjevu od 9 do 13.
The vaccine composition according to claim 1 comprising as active principle the conjugated protein hrEGFrP64K, wherein the final concentration of the total protein is in the range 1-12 mg/mL 
Sastav cjepiva prema zahtjevu 1, koji kao aktivni sastavni element sadrži konjugirani protein hrEGF-rP64K, naznačen time, da je konačna koncentracija ukupnog proteina u rasponu od 1 do 12 mg/mL.
A pharmaceutical composition, comprising 3a-hydroxy-3β-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, and one or more pharmaceutically-acceptable excipients for use in the treatment of obsessive compulsive disorder, post-traumatic stress disorder or social anxiety disorder in a human subject, wherein the composition provides steady state plasma levels of 3a-hydroxy-3β-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 5 ng/mL to 500 ng/mL for a duration of from 6 hours to 24 hours following administration. 
Farmaceutski sastav, naznačen time da sadrži 3a-hidroksi-3β-metoksimetil-21-(1’-imidazolil)-5a-pregnan-20-on ili njegovu farmaceutski prihvatljivu sol ili solvat i jedan ili više farmaceutski prihvatljivih ekscipijenata za upotrebu u liječenju opsesivno- kompulzivnog poremećaja, posttraumatskog stresnog poremećaja ili socijalnog anksioznog poremećaja u ljudskom subjektu, pri čemu sastav daje stacionarno stanje razina u plazmi 3a-hidroksi-3β-metoksimetil-21-(1’-imidazolil)-5a-pregnan-20-ona u rasponu od 5 ng/ml do 500 ng/ml u trajanju od 6 sati do 24 sata nakon davanja.
The pharmaceutical composition for use according to claim 1 or 2, wherein the composition provides steady state plasma levels of 3a-hydroxy-3β-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 50 ng/mL to 250 ng/mL. 
Farmaceutski sastav za upotrebu prema patentnom zahtjevu 1 ili 2, naznačen time da daje stacionarno stanje razine u plazmi 3a-hidroksi-3β-metoksimetil-21-(1’-imidazolil)-5a-pregnan-20-ona u rasponu od 50 ng/ml to 250 ng/ml.
Controllable ribbed thermoinsulative chamber (1): 
Upravljiva rebrasta termoizolacijska komora (1):
the chamber (1) has the inner seams (4) that define the ribbed structure shape and the maximum volume of the said chamber, 
komora (1) dodatno posjeduje unutarnje šavove (4) koji definiraju maksimalni volumen napuhavanja i daju komori rebrastu strukturu;
said chamber (1) is further equipped with the opening (6) for releasing the condensate out form the chamber (1), and 
da rečena komora (1) dodatno posjeduje otvor (6) za ispuštanje kondenzata iz komore (1); i
where the said chamber (1) is equipped with net-like structure or semi-permeable membranes (2) that enable forced deflation of the chamber (1) and their structural connection with the other chambers. 
gdje je rečena komora (1) opletena povezanom mrežastom strukturom ili polupropusnom membranom (2) koja omogućava forsirano ispuhavanje komore (1) i njeno strukturno povezivanje sa drugim komorama.
The article of clothing for the targeted body part thermal protection formed by one or more thermoinsulative chambers (1) defined in claim 1, and controlled by one or more control systems (12), characterized by that: 
Odjevni predmet s toplinskom zaštitom ciljanog dijela tijela, koji se sastoji od jedne ili više termoizolacijskih komora (1) definiranih u zahtjevu 1, te kontroliranih s jednim ili više upravljačkih sustava (12), naznačen time da:
where the said net-like structure or semi-permeable membranes (2) forms the connecting channel structures for air circulation and forced cooling via air stream from the nozzles (19) situated into said structures, and 
gdje rečeni mrežasti ili membranski spojevi (2) ujedno tvore spojne kanalne strukture koji omogućavaju strujanje i prinudno hlađenje strujom hladnog zraka iz mlaznica za hlađenje (19) koje su smještene unutar rečene strukture, i
The article of clothing according to the claim 2, characterised by that the control system (12) is equipped with special consumption control power system (13), while the lowed edges of the clothing has a detachable mounted elements for controlling one or more chamber (1) thicknesses. 
Odjevni predmet prema zahtjevu 2, naznačen time da je upravljački sustav (12) opremljen sa posebnim sustavom napajanja s kontrolom potrošnje (13), dok donji rub odjevnog predmeta posjeduje rastavljivo spojene pričvršćene elemente za upravljanje debljinom jedne ili više komora (1).
A binder composition according to claim 1, characterized in that the polyalkylene glycol is polyethylene glycol or a mixture of polyethylene glycol with polypropylene glycol. 
Vezivna smjesa prema zahtjevu 1, naznačena time da polialkilen glikol je polietilen glikol ili mješavina polietilen glikola sa polipropilen glikolom.
A binder composition according to any of claims 5 or 6 characterized in that the total amount of silane present is from 0.2% to 1.0% by weight based on the weight of the binder composition. 
Vezivna smjesa prema bilo kojem od zahtjeva 4 ili 5 naznačena time da je ukupna količina prisutnog silana od 0.2% do 1.0% težinski temeljeno na težini vezivne smjese.
Method of preparing a binder composition according to any of claims 1 to 6 comprising the following step: Preparing an alkaline aqueous mixture comprising a base resol phenol-aldehyde resin, an oxyanion and a polyalkylene glycol with 3 or more alkylene glycol units, wherein the oxyanion can form a stable complex with the resin present in said mixture, wherein the amount of alkali present in said mixture is sufficient to substantially prevent stable complex formation between the resin present in said mixture and the oxyanion, wherein the mixture has a molar ratio of alkali, expressed as hydroxyl ions, to phenol of from 1.0: 1 to 2.5: 1 
Postupak za dobivanje vezivne smjese prema bilo kojem od zahtjeva 1 do 6 naznačen time da sadrži slijedeći korak: pripremanje alkalne vodene smjese koja sadrži bazičnu resol fenol-aldehidnu smolu, oksianion i polialkilen glikol sa 3 ili više jedinica alkilen glikola, pri čemu oksianion može formirati stabilni kompleks sa smolom koja se nalazi u navedenoj smjesi, pri čemu je količina alkalija koja se nalazi u vezivnoj smjesi dovoljna da u osnovi spriječi formiranje stabilnog kompleksa između smole koja se nalazi u navedenoj smjesi i oksianiona, a pri čemu smjesa ima molarni omjer alkalija, izraženo kao hidroksilni ioni, prema fenolu od 1.0: 1 do 2.5:1, pri čemu je oksianion odabran iz skupine koju čine boratni, stanatni i aluminatni ioni, pri čemu polialkilen glikol je polietilen glikol ili mješavina polietilen glikola sa dodatnim polialkilen glikolom, i pri čemu je polialkilen glikol dodan u količini od 1% do 40% težinski temeljeno na ukupnoj težini vezivne smjese.
Article of bonded particulate material according to claim 14, wherein the article is a foundry mould, a foundry core or a feeder. 
Proizvod od vezanog čestičnog materijala prema zahtjevu 14, naznačen time da proizvod je kalup za lijevanje, jezgra za lijevanje ili pojilo.
A compound according to claim 9 wherein the inflammatory disease or associated pathology is asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation associated with restenosis and ischemic heart failure, stroke, renal disease or tumour metastasis. 
Spoj u skladu s patentnim zahtjevom 9, naznačen time, da su upalne bolesti ili s njima povezana patologija astma, reumatoidni artritis, COPD, rinitis, osteoartritis, psorijatični artritis, psorijaza, plućna fibroza, upala pluća, akutni respiratorni distres sindrom, perodontitis, multipla skleroza, gingivitis, ateroskleroza, neointimalna proliferacija povezana s restenozom i ishemijskim zatajenjem srca, moždani udar, bolest bubrega ili metastaza tumora.
reducing a compound of Formula VI to form a compound of Formula VII; and 
redukciju spoja Formule VI, čime se dobiva spoj Formule VII; te [image]
deprotecting a compound of Formula VII to form a compound of Formula VIII 
skidanje zaštite sa spoja Formule VII, čime se dobiva spoj Formule VIII [image]
A process for preparing a compound of Formula XXI comprising: 
Postupak za pripremu spoja Formule XXI [image] naznačen time, da obuhvaća:
reacting a compound of Formula IX with a compound of Formula in to form a compound of Formula X; 
reakciju spoja Formule IX [image] sa spojem Formule III [image] čime se dobiva spoj Formule X;
deprotecting a compound of Formula XV to form a compound of Formula XVI; 
-hal Formula XIV čime se dobiva spoj Formule XV; [image]
reacting a compound of Formula XVII with a compound of Formula M-A' or A' to form a compound of Formula XVIII; 
reakciju spoja Formule XVII sa spojem Formule M-A' ili A', čime se dobiva spoj Formule XVIII;
reacting a compound of Formula XVIII with a compound of Formula XIX to form a compound of Formula XX; and 
reakciju spoja Formule XVIII sa spojem Formule XIX [image] čime se dobiva spoj Formule XX; te [image]
deprotecting a compound of Formula XX to form a compound of Formula XXI wherein: 
skidanje zaštite sa spoja Formule XX, čime se dobiva spoj Formule XXI [image] pri čemu:
LG is a leaving group such as mesyl, tosyl or triflyl or a halogen; 
LG je odlazeća skupina, primjerice mezil, tozil ili triflil ili halogen;
reducing a compound of Formula XXIII to form a compound of Formula XXIV; and 
redukciju spoja Formule XXIII, čime se dobiva spoj Formule XXIV; te [image]
deprotecting a compound of Formula XXIV to form a compound of Formula XXV 
skidanje zaštite sa spoja Formule XXIV, čime se dobiva spoj Formule XXV [image]
reacting a compound of Formula XXIV with a compound of Formula XXVI Rt-COOH Formula XXVI to form a compound of Formula XXVII: 
koji obuhvaća: reakciju spoja Formule XXIV [image] sa spojem Formule XXVI Rt-COOH Formula XXVI čime se dobiva spoj Formule XXVII: pri čemu: